Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma

S. Kirishi, E. Tagaya, M. Ishii, K. Takeyama, K. Isono, M. Kondo, F. Shinya, J. Tamaoki (Tokyo, Fukushima, Japan)

Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Session: New clinical trials of asthma and COPD drugs
Session type: Poster Discussion
Number: 3399
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Kirishi, E. Tagaya, M. Ishii, K. Takeyama, K. Isono, M. Kondo, F. Shinya, J. Tamaoki (Tokyo, Fukushima, Japan). Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma. Eur Respir J 2013; 42: Suppl. 57, 3399

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of budesonide/formoterol maintenance and reliever therapy in mild asthma
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013

Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015


Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013


Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014


Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013


Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016

Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


The effect of treatment duration by inhaled glucocorticosteroids, on “cough variant asthma” in children
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013

LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015